nabu.science
MethodologyAboutContact

 

Reliability concern: This paper was retracted on 2021-01-28. See notice: 10.1039/d1ra90042k.

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-FAEB52EA·Framework v5.0·Pipeline v0.4·Evaluated 30 May 2026·OECD: 3.1 Basic medicine·Subfield: Cancer Research·Basis: Full text·Type: Laboratory experiment

Retracted Article: LncRNA OIP5-AS1 contributes to ox-LDL-induced inflammation and oxidative stress through regulating the miR-128-3p/CDKN2A axis in macrophages.

Li et al.Li, Cao, Wang et al.·2019·RSC advances·10.1039/c9ra08322g ↗

In brief

An incremental ceRNA-axis characterisation in ox-LDL-treated THP1 cells undermined by statistical errors and methods-section template contamination.

ReliabilityConcerns4 of 4 checks completeRead the 3 entries ↓
Abstract

Long non-coding RNA OIP5-AS1 (lncRNA OIP5-AS1) and microRNA-128-3p (miRNA-128-3p) have been reported to play significant roles in human diseases. However, their role in atherosclerosis (AS) has been less studied. The aim of this research was to reveal the roles and functional mechanisms of OIP5-AS1 and miRNA-128-3p in AS development. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blot assays were performed to detect gene expression. Cell proliferation and apoptosis were assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry analysis, respectively. In addition, ELISA was employed to determine the levels of interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF)-α. Oxidative stress was examined using a relevant kit. Furthermore, the interaction between miR-128-3p and OIP5-AS1 or cyclin-dependent kinase inhibitor 2A (CDKN2A) was predicted using StarBase, and then confirmed using the dual-luciferase reporter assay or the RNA immunoprecipitation (RIP) assay. We found that OIP5-AS1 and CDKN2A levels were upregulated and the miR-128-3p level was downregulated in oxidized low-density lipoprotein (ox-LDL)-induced THP1 cells. OIP5-AS1 knockdown weakened the regulatory effect of ox-LDL on cell progression. Interestingly, OIP5-AS1 directly interacted with miR-128-3p and miR-128-3p-targeted CDKN2A. Furthermore, OIP5-AS1 regulated ox-LDL-induced cell progression through modulating miR-128-3p expression, and miR-128-3p exerted its influence by modulating the CDKN2A level. Finally, we confirmed that OIP5-AS1 suppressed miR-128-3p expression to increase the level of CDKN2A. In conclusion, our findings demonstrate that OIP5-AS1 knockdown repressed the effect of ox-LDL on cell progression through regulating the miR-128-3p/CDKN2A axis, providing a potential target for the treatment of AS.

Strengths · Limitations

Strengths

#methodological rigour

Coherent multi-step mechanistic validation chain

The study progresses logically from expression profiling through knockdown, bioinformatic prediction, dual-luciferase and RIP interaction validation, and rescue experiments, establishing a complete OIP5-AS1/miR-128-3p/CDKN2A regulatory axis.

↳ Results, Figs. 1–7

#methodological rigour

Multiple siRNA sequences confirm knockdown specificity

Three independent siRNA sequences targeting OIP5-AS1 were tested, with knockdown efficiency confirmed by qRT-PCR before selecting the most effective construct for downstream experiments.

↳ Fig. 2A

#contribution

Dual interaction validation methods

The miR-128-3p interaction with OIP5-AS1 is confirmed by both dual-luciferase reporter assay and RNA immunoprecipitation, providing independent lines of evidence for the proposed binding.

↳ Figs. 3B–C

Limitations

#methodological rigour

Methods describe constructs never used in experiments

The Plasmid and Transfection section describes cloning MALAT1 and TRIM65 overexpression vectors into pcDNA3.1, yet neither gene appears anywhere in the Results or Discussion. This methods–results mismatch is consistent with template contamination or manuscript assembly error and raises concerns about manuscript preparation quality.

↳ Methods, Plasmid and Transfection

#methodological rigour

Inappropriate statistical analysis for multi-group comparisons

Student's t-test is applied throughout, including for dose-response experiments (4 concentrations) and rescue experiments (4 conditions), without ANOVA or multiple comparison correction. This inflates Type I error rates across the numerous endpoints tested.

↳ Statistical Analysis; Figs. 2–7

#contribution

Therapeutic claims exceed single-cell-line evidence

The paper claims to provide 'a theoretical basis for the treatment of AS' based entirely on THP1 cell line experiments without animal models, primary macrophages, or patient data. No differentiation of THP1 monocytes into macrophages is reported, yet the work is framed as macrophage biology.

↳ Abstract; Conclusion; Methods, Cell Culture

Does this match your read? Add your assessment ↓

Withdrawn — shown for reference only

Nabu Commentary

This paper follows a well-established lncRNA-miRNA sponge validation template to characterise the OIP5-AS1/miR-128-3p/CDKN2A axis in ox-LDL-stimulated THP1 cells. The experimental chain from expression profiling through interaction validation to rescue experiments is logically structured and internally consistent. However, two methodological issues significantly limit confidence: the Methods section describes MALAT1 and TRIM65 overexpression constructs that appear nowhere in the Results, suggesting template contamination in manuscript preparation, and Student's t-test is applied throughout to multi-group comparisons without appropriate correction. The confinement of all experiments to a single undifferentiated cell line, combined with therapeutic claims that substantially exceed the in vitro evidence, places the paper in the lower range of methodologically competent mechanistic studies.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.5±0.1

Contribution
2.8

The paper characterises a new OIP5-AS1/miR-128-3p/CDKN2A regulatory axis in ox-LDL-stimulated THP1 cells, adding an incremental mechanistic node to a well-populated lncRNA-miRNA sponge literature. The advance is real but modest, limited by single-cell-line scope and claims of therapeutic relevance that exceed what in vitro data can support.

Abstract; Results Figs. 1–7; Conclusion

providing a potential target for the treatment of AS

Methodological Rigour
2.3

The experimental pipeline follows an appropriate lncRNA-miRNA sponge validation sequence (expression profiling, knockdown with multiple siRNAs, luciferase/RIP validation, rescue experiments), but Student's t-test is applied throughout to multi-group comparisons without ANOVA or multiple comparison correction, and the Methods section contains template contamination describing MALAT1 and TRIM65 constructs never used in any experiment.

Statistical Analysis section; Methods, Plasmid and Transfection; Fig. 2A

The sequences of MALAT1 and TRIM65 were cloned into the pcDNA3.1 plasmid

Reporting
3.1

The paper is clearly structured with a logical progression from expression profiling through mechanistic validation and rescue experiments. However, qualifying language consistently overclaims therapeutic relevance from single-cell-line in vitro evidence, and the unexplained MALAT1/TRIM65 mention in Methods introduces confusion.

Abstract; Conclusion; Methods, Plasmid and Transfection

a theoretical basis for the treatment of AS

Positioning
2.6

The Introduction provides adequate background on lncRNAs, miR-128-3p, and CDKN2A in disease contexts, and the Discussion cites relevant prior work. However, no limitations section is present, and the Discussion is largely confirmatory without engaging with alternative interpretations or boundary conditions.

Introduction; Discussion

Lower confidence on Contribution, Methodological Rigour — domain match limited.

Reliability

Concerns4 of 4 checks


Internal CoherenceNoted

The Methods section describes cloning MALAT1 and TRIM65 overexpression vectors that are never used in any reported experiment, indicating template contamination or manuscript preparation error. The core experimental chain (OIP5-AS1/miR-128-3p/CDKN2A) is internally consistent across abstract, results, and conclusions, but translational claims in the abstract and conclusion substantially exceed the single-cell-line in vitro evidence.

Research ConductNoted

No ethics approval, conflicts of interest, or data availability statements are provided. For a 2020 cell-line-only study this is not automatically a red flag but represents a gap in reporting standards.

Flags: 0 declared / 5 total

Reference IntegrityClean

All 36 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordConcern

This paper was retracted on 2021-01-28. See notice: 10.1039/d1ra90042k.

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cardiovascular · Ischemic heart disease
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesLarge
CitationsFWCI 0.2
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

Effects of OIP5-AS1 knockdown on inflammation and oxidative stress were only demonstrated in controlled in vitro THP1 cell experiments without animal or human validation.

From the paper
“providing a potential target for the treatment of AS”

The paper names a therapeutic use of its findings as a drug target for atherosclerosis but does not specify who would develop or apply such a treatment.

Pathway

Pharmaceutical and preclinical researchers could develop OIP5-AS1 inhibitors or miR-128-3p agonists as anti-atherosclerotic therapies targeting macrophage inflammation in arterial plaques.

Barrier

All evidence is from in vitro THP1 cell experiments with no animal model or human tissue validation, and targeted delivery of RNA therapeutics to plaque macrophages remains unsolved.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Technical feasibility of a long read, fourth generation sequencing platform in diagnostic profiling of clinical routine samples: a proof-of-concept study

    Vitale, Colarossi, Russo, et al. · 2026 · Clinical medicine

    Primary claim

    The adapted ONT workflow demonstrated high concordance rate in detecting clinically relevant molecular alterations on short-read fragments, achieving comparable accuracy with standardized second generation NGS platforms on tissue and liquid biopsy samples.

    Tentative
    Evidence Score
    2.7±0.2
    Reliability
    Caveats
  2. Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis

    Cortes, Haiderali, Huang, et al. · 2023 · Basic medicine

    Primary claim

    Neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab confers benefits in response and survival outcomes versus alternative neoadjuvant treatments for early-stage TNBC.

    Tentative
    Evidence Score
    3.3±0.2
    Reliability
    Caveats
  3. Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test

    Weihua Zeng, S. Guo-Dong Li, Shuo Li, et al. · 2026 · Clinical medicine

    Primary claim

    MethylScan achieved an area under the receiver operating characteristic curve (AUROC) of 0.938 (95% CI: 0.920 to 0.954), with a sensitivity of 63.3%

    Supported
    Evidence Score
    3.7±0.2
    Reliability
    Caveats

How the rubric works →